Press Releases

Press release: Online availability of Sanofi’s half-year financial report for 2025

Press Release: Q2: double-digit sales and solid business EPS growth. 2025 sales guidance is now high single-digit growth, at upper end of range

Press Release: Sanofi’s SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma

Press Release: Sanofi’s Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma

Press Release: Sanofi to acquire Vicebio, expanding respiratory vaccines pipeline

Press Release: Sanofi completes acquisition of Blueprint Medicines

Press Release: Sanofi announces extension of Blueprint tender offer

Press Release: Sanofi’s SAR446597 earns fast track designation in the US for geographic atrophy due to age-related macular degeneration

Press release: Availability of the Q2 2025 Aide mémoire

Press Release: Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy

Press Release: Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation

Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myeloma

Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

Press release: Sanofi successfully prices €1.5 billion bond issue

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

Press Release: Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season

Press release: Sanofi Launches 2025 Global Employee Stock Purchase Plan

Press Release: ASCO: new Sarclisa data support subcutaneous administration with on-body injector

Press Release: Rilzabrutinib granted orphan drug designation in the US for sickle cell disease

Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology